Mammary Cell News Volume 8.06 | Feb 18 2016

CDCP1 Cleavage Is Necessary for Homodimerization-Induced Migration of Triple-Negative Breast Cancer
Investigators observed that cleaved membrane-bound isoform (CUB)-domain containing protein 1 (CDCP1), compared with full-length CDCP1, induced a dramatic increase in phosphorylation of the migration-associated proteins: PKCδ, ERK1/2 and p38 mitogen-activated protein kinase in HEK 293T. [Oncogene] Abstract

Loss of MLCK Leads to Disruption of Cell-Cell Adhesion and Invasive Behavior of Breast Epithelial Cells via Increased Expression of EGFR and ERK/JNK Signaling
To gain insights into the role of myosin light chain kinase (MLCK) in breast cancer, researchers perturbed its function using small interfering RNA (siRNA) or pharmacological inhibition in untransformed breast epithelial cells. Loss of MLCK by siRNAs led to increased cell migration and invasion, disruption of cell–cell adhesions and enhanced formation of focal adhesions at the leading edge of migratory cells. [Oncogene] Abstract

Identification of Novel Pathways Linking Epithelial-to-Mesenchymal Transition with Resistance to HER2-Targeted Therapy
To identify pathways linked to resistance, investigators generated human epidermal growth factor receptor 2 (HER2)-positive breast cancer cell lines which are resistant to either lapatinib or AZD8931, two pan-HER family kinase inhibitors. Resistance was HER2 independent and was associated with epithelial-to-mesenchymal transition, resulting in increased proliferation and migration of the resistant cells. [Oncotarget] Full Article

Oxidative Stress Contributes to the Tamoxifen-Induced Killing of Breast Cancer Cells: Implications for Tamoxifen Therapy and Resistance
Researchers showed that concentrations of tamoxifen and its metabolites, which accumulate in tumors of patients, killed both estrogen receptor-α (ERα)-positive and ERα-negative breast cancer cells. [Sci Rep] Full Article

Selective Inhibition of EZH2 by ZLD1039 Blocks H3K27 Methylation and Leads to Potent Anti-Tumor Activity in Breast Cancer
Scientists described ZLD1039 a potent, highly selective, and orally bioavailable small molecule inhibitor of enhancer of zeste homolog 2 (EZH2), which inhibited breast tumor growth and metastasis. [Sci Rep] Full Article

Role of Apoptosis-Related miRNAs in Resveratrol-Induced Breast Cancer Cell Death
The authors demonstrated that resveratrol regulates apoptotic and cell cycle machinery in breast cancer cells by modulating key tumor-suppressive miRNAs including miR-125b-5p, miR-200c-3p, miR-409-3p, miR-122-5p and miR-542-3p. [Cell Death Dis] Full Article

ZEB1 Upregulates VEGF Expression and Stimulates Angiogenesis in Breast Cancer
Scientists presented the novel finding that conditioned medium derived from zinc finger E-box binding homeobox 1 (ZEB1)-expressing MDA-MB-231 cells significantly increased the capillary tube formation of human umbilical vein endothelial cells, whereas ZEB1 knockdown by RNA interference had the opposite effect. [PLoS One] Full Article

ELF5 and DOK7 Regulation in Anti-Estrogen Treated Cells and Tumors
Researchers characterized the expression of hormone receptors, and the mRNA and DNA methylation levels of docking protein 7 (DOK7), and E74-like factor 5 (ELF5), in 21 novel tamoxifen-resistant cell lines and extended the findings to primary and recurrent human breast tumors. [Cancer Cell Int] Full Article

CLINICAL RESEARCH

Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology–Genomic Integration Analysis
Researchers aimed to assess the degree of microenvironmental heterogeneity in breast cancer and correlate this with genomic and clinical parameters. [PLoS Med] Full Article | Press Release

BRCA1 and BRCA2 Mutation Testing in Young Women with Breast Cancer
The authors aimed to describe the use of BRCA testing and to evaluate how concerns about genetic risk and use of genetic information affect subsequent treatment decisions in young women with breast cancer. [JAMA Oncol] Abstract | Press Release

Etirinotecan Pegol for the Treatment of Breast Cancer
The review examines etirinotecan pegol as a promising new agent for the treatment of refractory metastatic breast cancer. [Expert Opin Pharmacother] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Seven Bridges Goes Live with Cancer Genomics Cloud Pilot
Seven Bridges announced that its system was selected to develop as part of the National Cancer Institute’s Cloud pilot program is open to researchers worldwide. The Seven Bridges Cancer Genomics Cloud is the first complete ecosystem to give cancer researchers immediate access to one of the world’s largest genomic datasets — The Cancer Genome Atlas — and the computational resources to analyze it. [Seven Bridges] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

NEW Postdoctoral Fellowship – Genetic and Epigenetic Variability in Breast Cancer (The University of Tennessee Health Science Center)

NEW Clinical Research Fellow – Breast Pathology (Institute of Cancer Research)

Lead Bioinformatician – Breast Cancer Research (Institute of Cancer Research)

Pathologist – Breast/Gastrointestinal/Genitourinary Cancer (Beth Israel Deaconess Medical Center)

Postdoctoral Fellowships – Breast and Prostate Cancer (Baylor College of Medicine)

Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellowship – Breast Cancer Biology (Washington University School of Medicine)

Professorship – Clinical Breast Cancer Research (University of Leeds)

Clinical Pathways Associate – Cancer Therapeutics (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellowship – Breast Cancer Development (University of Pennsylvania)

Postdoctoral Fellowship – Breast Cancer Translational Research (University of Bern)

Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.